Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (SHA:688505)

China flag China · Delayed Price · Currency is CNY
8.68
+0.04 (0.46%)
Feb 27, 2026, 3:00 PM CST
Market Cap7.02B +16.8%
Revenue (ttm)711.63M +2.9%
Net Income-62.67M
EPS-0.08
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividend0.03 (0.35%)
Ex-Dividend DateJul 18, 2025
Volume3,547,546
Average Volume5,586,644
Open8.60
Previous Close8.64
Day's Range8.58 - 8.69
52-Week Range6.73 - 11.69
Beta0.13
RSI48.89
Earnings DateMar 31, 2026

About SHA:688505

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clinical trials for tumors; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC, which is in phase I clinical trial for tumors; and H... [Read more]

Sector Healthcare
Founded 1996
Employees 899
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688505
Full Company Profile

Financial Performance

In 2024, SHA:688505's revenue was 709.40 million, a decrease of -16.61% compared to the previous year's 850.73 million. Earnings were 39.73 million, a decrease of -63.42%.

Financial Statements